Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00506805

Enrollment

Registered

2007-07-25

Start date

2007-06-30

Completion date

2010-03-31

Last updated

2012-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

solid tumor malignancy; Hsp90

Brief summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Interventions

DRUGSNX-5422

dose escalated, tablets every other day; undetermined duration until disease progression

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \>18 years old * histologically confirmed solid tumor malignancy * refractory to available therapy or for which no therapy is available * adequate organ function

Exclusion criteria

* CNS malignancy * significant GI disease * at risk for prolonged QT interval

Design outcomes

Primary

Measure	Time frame
adverse events and other safety assessments	continuous

Secondary

Measure	Time frame
tumor response measured by X-rays or scans	after every 2 cycles

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026